Thinly traded Chembio Diagnostics (CEMI +4.2%) promptly erases a 1.6% decline after SA Pro contributor Paul Nouri's article comes out of embargo. Nouri says the company could earn $0.45/share by 2015.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs